Advanced

Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases

van Assen, S.; Elkayam, O.; Agmon-Levin, N.; Cervera, R.; Doran, M. F.; Dougados, M.; Emery, P.; Geborek, Pierre LU ; Ioannidis, J. P. A. and Jayne, D. R. W., et al. (2011) In Autoimmunity Reviews 10(6). p.341-352
Abstract
Objectives: To present the systematic literature review (SLR), which formed the basis for the European League Against Rheumatism (EULAR) evidence-based recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD). Methods: AIIRD, vaccines and immunomodulating drugs, as well as eight key questions were defined by the multidisciplinary expert committee commissioned by EULAR for developing the recommendations. A SLR was performed using MedLine through October 2009 and including data from meta-analyses, systematic reviews, randomized trials, and observational studies, excluding case series with participants. Articles in English and regarding patients years of age, were eligible. Results: Several... (More)
Objectives: To present the systematic literature review (SLR), which formed the basis for the European League Against Rheumatism (EULAR) evidence-based recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD). Methods: AIIRD, vaccines and immunomodulating drugs, as well as eight key questions were defined by the multidisciplinary expert committee commissioned by EULAR for developing the recommendations. A SLR was performed using MedLine through October 2009 and including data from meta-analyses, systematic reviews, randomized trials, and observational studies, excluding case series with participants. Articles in English and regarding patients years of age, were eligible. Results: Several vaccine-preventable infections (VPI) occur more often in AIIRD-patients and most vaccines are efficacious in AIIRD-patients, even when treated with immunomodulating agents, except rituximab. There does not appear to be an increase in vaccination-related harms in vaccinated patients with AIIRD in comparison with unvaccinated patients with AIIRD. However, these studies are underpowered and therefore not conclusive. Conclusion: Based on the current evidence from the literature, recommendations for vaccination in patients with AIIRD were made. However, more research is needed in particular regarding incidence of VPI, harms of vaccination and the influence of (new and established) immunomodulating agents on vaccination efficacy. (C) 2011 Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Autoimmunity Reviews
volume
10
issue
6
pages
341 - 352
publisher
Elsevier
external identifiers
  • wos:000290059400009
  • scopus:79953161956
ISSN
1873-0183
DOI
10.1016/j.autrev.2010.12.003
language
English
LU publication?
yes
id
1851e9b6-b27a-4510-ae67-c06672c2dd78 (old id 1964674)
date added to LUP
2011-06-01 10:39:43
date last changed
2017-10-01 03:21:22
@article{1851e9b6-b27a-4510-ae67-c06672c2dd78,
  abstract     = {Objectives: To present the systematic literature review (SLR), which formed the basis for the European League Against Rheumatism (EULAR) evidence-based recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD). Methods: AIIRD, vaccines and immunomodulating drugs, as well as eight key questions were defined by the multidisciplinary expert committee commissioned by EULAR for developing the recommendations. A SLR was performed using MedLine through October 2009 and including data from meta-analyses, systematic reviews, randomized trials, and observational studies, excluding case series with participants. Articles in English and regarding patients years of age, were eligible. Results: Several vaccine-preventable infections (VPI) occur more often in AIIRD-patients and most vaccines are efficacious in AIIRD-patients, even when treated with immunomodulating agents, except rituximab. There does not appear to be an increase in vaccination-related harms in vaccinated patients with AIIRD in comparison with unvaccinated patients with AIIRD. However, these studies are underpowered and therefore not conclusive. Conclusion: Based on the current evidence from the literature, recommendations for vaccination in patients with AIIRD were made. However, more research is needed in particular regarding incidence of VPI, harms of vaccination and the influence of (new and established) immunomodulating agents on vaccination efficacy. (C) 2011 Elsevier B.V. All rights reserved.},
  author       = {van Assen, S. and Elkayam, O. and Agmon-Levin, N. and Cervera, R. and Doran, M. F. and Dougados, M. and Emery, P. and Geborek, Pierre and Ioannidis, J. P. A. and Jayne, D. R. W. and Kallenberg, C. G. M. and Mueller-Ladner, U. and Shoenfeld, Y. and Stojanovich, L. and Valesini, G. and Wulffraat, N. M. and Bijl, M.},
  issn         = {1873-0183},
  language     = {eng},
  number       = {6},
  pages        = {341--352},
  publisher    = {Elsevier},
  series       = {Autoimmunity Reviews},
  title        = {Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases},
  url          = {http://dx.doi.org/10.1016/j.autrev.2010.12.003},
  volume       = {10},
  year         = {2011},
}